[A change of tumor PyNPase level at intraperitoneal and intravenous administrations of paclitaxel].
A level of PyNPase activity was measured after intraperitoneal (ip) and intravenous (i.v.) administrations of paclitaxel on the animal model. Nude mice received the subcutaneous implantation of WiDr cells. About 3 weeks later, the ip and i.v. administrations of paclitaxel were performed 2 times at 20 mg/kg and 15 mg/kg, respectively. About 1 week later, the mice were sacrificed. The level of PyNPase activity was measured by the ELISA method. The level of PyNPase of ip and i.v. was higher than that of the control group, but the level of PyNPase revealed no significant difference between ip and i.v.. This result suggested that intraperitoneal administration of paclitaxel enhanced an efficiency of 5'-DFUR and capecitabine as much as intravenous administration of paclitaxel.
Maruyama
Michio
M
Dept of Surgery, Ohkubo Hospital.
Ebuchi
Masakazu
M
D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D005260:Female; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental / Q000201:enzymology*; D017239:Paclitaxel / Q000008:administration & dosage*; D010430:Pentosyltransferases / Q000032:analysis*; D057845:Pyrimidine Phosphorylases
D000964:Antimetabolites, Antineoplastic; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; D017239:Paclitaxel